In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diagnostics In 2016: From Alere To Zika

Executive Summary

No significant trends emerged in diagnostics M&A or financing this past year, which did see the introduction of several government-funded initiatives, elements of which will bolster diagnostics innovation. As in other sectors of health care, the biggest question is how the incoming Trump administration could change US regulatory and funding policies.

Advertisement

Related Content

Science Matters: Insights Into Gut-Brain Signaling Raise Hopes For Treating Neurological Disorders
Abbott Steps Up Effort To Abandon Alere Deal
FDA Puts Lab-Developed Test Oversight Plans On Hold
Industry: Next-Gen Sequencing Draft Guidances Have Good Ideas But Need Tweaks
Liquid Biopsy, Particle-Beam Radiotherapy Get 'Moonshot' Commitments
How Immuno-Oncology Is Turning Biomarker Development On Its Head
Rapid Infectious Disease Testing Picks Up Speed
Diagnostics In 2015: Past Trends Coalesce, New Roads Open
When Illumina Buys Roche: The Dawning Of The Era Of Diagnostics Dominance
Matchmaking And Integration In The New World Of Diagnostics M&A

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel